Recursion Pharmaceuticals, Inc.
RXRX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001601830
In the last 90 days, Recursion Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 5 sales; 347 institutions reported holding it in 13F filings for Q2 2026, worth $1.33B in total; ARK Invest is the only superinvestor holding it.
Key figures
- Market capClose on Nov 11, 2026
- $2.24B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $701.2K in total
- 5
- 13F holdersQ2 2026, +13 vs. previous quarter
- 347
- 13F valueReported value at the end of Q2 2026
- $1.33B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $74.7M
- +26.9% year over year
- Net income, FY2025
- -$644.8M
- No comparable prior period
- Free cash flow, FY2025
- -$378.3M
- No comparable prior period
- Revenue, Q3 FY2026
- $18.6M
- +258.5% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $644.8M (863.4% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 142.3M
- Shares sold short
- Change
- −19.7M
- −12.1% vs. previous
- Days to cover
- 6.10
- At average daily volume
Superinvestors holding RXRX, Q2 2026
Go to the superinvestors tab1 superinvestor reports holding Recursion Pharmaceuticals, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
ARK Invest
Cathie Wood
1.0%
Recursion Pharmaceuticals, Inc.'s share of the portfolio
- Shares
- 41,337,632
- Value
- $151.7M
Latest insider trades
See all insider tradesOpen-market purchases and sales by Recursion Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 4, 2026 (view filing)5:12 PM ET | Nov 3 | 1 day | Borgeson BlakeDirector | SSaleClass A Common Stock | −40.0K | $3.88 | −$155.2K | −0.7%6.07M after | 10b5-1 |
| Oct 7, 2026 (view filing)6:08 PM ET | Oct 6 | 1 day | Borgeson BlakeDirector | SSaleClass A Common Stock | −50.0K | $4.84 | −$242.0K | −0.8%6.11M after | 10b5-1 |
| Oct 7, 2026 (view filing)6:08 PM ET | Oct 6 | 1 day | Hershberg RobertDirector | SSaleClass A Common Stock | −25.0K | $5.00 | −$125.0K | −13.4%162.2K after | 10b5-1 |
| Sep 10, 2026 (view filing)5:55 PM ET | Sep 8 | 2 days | Khan NajatCEO and President | SSaleClass A Common Stock | −22.4K | $3.52 | −$78.8K | −1.1%2.07M after | 10b5-1 |
| Sep 2, 2026 (view filing)6:01 PM ET | Sep 1 | 1 day | Borgeson BlakeDirector | SSaleClass A Common Stock | −30.0K | $3.34 | −$100.2K | −0.5%6.16M after | 10b5-1 |
| Aug 6, 2026 (view filing)5:09 PM ET | Aug 4 | 2 days | Borgeson BlakeDirector | SSaleClass A Common Stock | −30.0K | $3.25 | −$97.5K | −0.5%6.19M after | 10b5-1 |
| Jul 9, 2026 (view filing)6:04 PM ET | Jul 7 | 2 days | Borgeson BlakeDirector | SSaleClass A Common Stock | −40.0K | $3.96 | −$158.5K | −0.6%6.22M after | 10b5-1 |
| Jun 22, 2026 (view filing) | Jun 18 | 4 days | Bumpus NamandjeDirector | SSaleClass A Common Stock | −3.96K | $3.18 | −$12.6K | −3.0%127.6K after | 10b5-1 |
| Jun 5, 2026 (view filing) | Jun 5 | Same day | Khan NajatCEO and President | SSaleClass A Common Stock | −23.6K | $3.58 | −$84.4K | −1.1%2.18M after | 10b5-1 |
| Jun 5, 2026 (view filing) | Jun 5 | Same day | Gibson ChristopherDirector | SSaleClass A Common Stock | −40.0K | $3.62 | −$144.8K | −4.3%883.7K after | 10b5-1 |
Top 10 13F holders, Q2 2026
See all 347 holdersThe largest institutional positions in Recursion Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 50,304,691 | $184.6M | 0.00% | +7,112,385+16.5% | Added |
| ARK Investment Management LLCSuperinvestorARK Invest | 41,337,632 | $151.7M | 0.98% | +1,124,863+2.8% | Added |
| State Street Corp | 34,706,130 | $127.4M | 0.00% | +6,215,492+21.8% | Added |
| Vanguard Portfolio Management LLC | 31,131,599 | $114.3M | 0.01% | +8,372,499+36.8% | Added |
| Baillie Gifford & Co | 23,487,907 | $86.2M | 0.08% | −187,500−0.8% | Reduced |
| Vanguard Capital Management LLC | 22,765,940 | $83.6M | 0.00% | +521,553+2.3% | Added |
| Geode Capital Management, LLC | 13,819,135 | $50.7M | 0.00% | +1,544,051+12.6% | Added |
| Softbank Group Corp | 13,636,515 | $50.0M | 0.28% | 00.0% | Unchanged |
| MIC Capital Management UK LLP | 9,644,033 | $35.4M | 8.98% | +10.0% | Added |
| UBS Group AG | 8,947,102 | $32.8M | 0.01% | +3,845,865+75.4% | Added |
Holders of 5% or more of RXRX
See all 6 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Recursion Pharmaceuticals, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 8.50%44.5M shares | +1.30 ppfrom 7.20% | Oct 22, 20245 filings | Jul 29, 2026 | SEC |
| ARK Investment Management LLCSuperinvestorARK Invest | 13G/A | 7.25%37.3M shares | −1.22 ppfrom 8.47% | Jan 29, 20244 filings | Feb 3, 2026 | SEC |
| Baillie Gifford & Co | 13G/A | 6.50%24.9M shares | −2.70 ppfrom 9.20% | May 6, 20216 filings | Feb 12, 2025 | SEC |
| Vanguard Portfolio Management LLC | 13G | 5.97%31.4M shares | New | Jul 31, 20261 filing | Jul 31, 2026 | SEC |
| State Street Corp | 13G | 5.60%30.0M shares | −1.00 ppfrom 6.60% | Jan 24, 20245 filings | Nov 10, 2026 | SEC |